Bryan Roberts, Ph.D.

Managing General Partner, Venrock Associates

Bryan Roberts joined Venrock as a Kauffman Fellow in 1997. He is based in Venrock's Palo Alto office and focuses on a broad range of healthcare investments.

Bryan currently serves on the Board of Directors of a number of private companies including Achaogen, Coderyte, Fate Therapeutics, Ikaria, Ironwood, Satiety and Castlight. Past investments include athenahealth (NASDAQ: ATHN), Xenoport (NASDAQ: XNPT); Sirna Therapeutics (acquired by Merck) and Illumina (NASDAQ: ILMN).

Immediately prior to joining Venrock, Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He previously held positions in corporate finance at Kidder, Peabody & Co and received his B.A. from Dartmouth College. Bryan was named a Henry Crown Fellow by the Aspen Institute in 2006, he was named to healthspottr's 2009 Future Health 100 list and was the highest-ranking healthcare investor on Forbes' Midas List in 2008 and 2009.

MANAGEMENT TEAM

BOARD OF DIRECTORS